GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer
- First Posted Date
- 2004-03-03
- Last Posted Date
- 2010-12-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 408
- Registration Number
- NCT00078572
Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer
- First Posted Date
- 2004-01-09
- Last Posted Date
- 2015-05-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 580
- Registration Number
- NCT00075270
- Locations
- 🇹🇷
GSK Investigational Site, Istanbul, Turkey
A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- Drug: GW572016 (lapatinib)
- First Posted Date
- 2003-11-17
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 131
- Registration Number
- NCT00073008
- Locations
- 🇨🇦
GSK Investigational Site, Levis, Quebec, Canada
Clinical Study Of Schizophrenia in Both Men and Women
- Conditions
- Schizophrenia
- First Posted Date
- 2003-10-31
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 176
- Registration Number
- NCT00071747
- Locations
- 🇺🇸
GSK Investigational Site, Milwaukee, Wisconsin, United States
OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction
- Conditions
- Thromboembolism
- Interventions
- Other: Control - UFH not indicatedDrug: Control - UFH
- First Posted Date
- 2003-10-17
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12092
- Registration Number
- NCT00064428
Study Of AVANDAMET® With Or Without Insulin In Type II Diabetes Mellitus Patients. AVANDAMET® is a Registered Trademark of the GSK Group of Companies.
- First Posted Date
- 2003-10-03
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 272
- Registration Number
- NCT00069836
- Locations
- 🇪🇸
GSK Investigational Site, Vigo/Pontevedra, Spain
Seasonal Affective Depression (SAD) Study
- Conditions
- Depressive Disorder
- Interventions
- First Posted Date
- 2003-09-26
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 250
- Registration Number
- NCT00069459
- Locations
- 🇺🇸
GSK Investigational Site, Middleton, Wisconsin, United States
Bipolar Study in Adults at Least 18 Years of Age
- First Posted Date
- 2003-09-05
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1200
- Registration Number
- NCT00067938
- Locations
- 🇺🇸
GSK Investigational Site, West Allis, Wisconsin, United States
A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2003-09-05
- Last Posted Date
- 2018-03-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 190
- Registration Number
- NCT00067951
- Locations
- 🇳🇿
GSK Investigational Site, Wellington, New Zealand
Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
- Conditions
- Irritable ColonIrritable Bowel Syndrome (IBS)
- First Posted Date
- 2003-08-25
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 702
- Registration Number
- NCT00067561
- Locations
- 🇦🇺
GSK Investigational Site, Nedlands, Western Australia, Australia